Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.
Bayer has seen many an M&A opportunity come and go when it comes to bolstering its animal health unit. But once it jettisons its plastics unit--a move that could generate some extra dough--it might finally be ready to strike a deal.
Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.
French medical diagnostics outfit Labco is selling out to U.K. private equity firm Cinven for €1.2 billion ($1.3 billion), shifting gears after abandoning its previously announced IPO.
U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.
One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.
Retrophin is selling its recently acquired coupon for a speedy FDA approval to Sanofi for $245 million in cash.
Despite the M&A wave across biopharma that doesn't show signs of slowing, Bavarian Nordic's top dog has said his company isn't interested in getting involved.
Valeant CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happening left and right in the sector, some of pharma's recent acquisitions "are not going to work."
A group of Chinese biotech heavyweights are banding together to buy Ambrx, R&D partner to the likes of Bristol-Myers Squibb and Merck, in hopes of making the company a go-to collaborator in their native country.